Avedro Inc., a Waltham medical device and drug company, announced Tuesday the completion of a $43 million Series D financing.
The financing was led by Abingworth along with a significant investment by Third Point; Avedro’s other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures, and Echelon Ventures, the company said in a press release.
“Proceeds from this financing will allow us to execute on both our global commercialization strategy and our US FDA approval strategy,” David Muller, Avedro’s chief executive, said in a statement. “In addition, Avedro plans to use proceeds from this financing to continue its aggressive research and development efforts. These are aimed at expanding the use of corneal crosslinking into applications such as cataract and refractive surgery, which represent billion dollar market opportunities.”
Avedro said it has now raised $87 million to date.